The FDA expands approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

European Commission Expands Skyrizi Label to Younger Patients AbbVie (NYSE:ABBV) has received approval from the European ...

The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are ...

AbbVie ABBV announced that the European Commission (EC) has approved its blockbuster immunology drug, Skyrizi (risankizumab), ...

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...

Pharmaceutical maker AbbVie said the Food and Drug Administration approved its Skyrizi to treat pediatric patients with psoriasis. Skyrizi, or risankizumab-rzaa, will be available to patients aged six ...

- SKYRIZI® (risankizumab-rzaa) met the primary endpoint of ACR20 at week 24 in two pivotal studies, demonstrating significant improvement in joint symptoms, including swollen, tender and painful ...

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...